Valuation : Omeros Corporation

Market Cap 1.37B 1.18B 1.11B 1.01B 1.89B 130B 1.9B 13.16B 5.09B 66.44B 5.15B 5.04B 212B P/E 2026 *
21.3x
P/E 2027 * 19x
Enterprise Value 1.37B 1.18B 1.11B 1.01B 1.89B 130B 1.9B 13.16B 5.09B 66.44B 5.15B 5.04B 212B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 6.94x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.84%
1 week+1.83%
Current month+0.85%
1 month+44.11%
3 months+93.56%
6 months+64.21%
Current year+10.33%
1 week 18.44
Extreme 18.44
19.47
1 month 13
Extreme 13
19.65
Current year 6.7
Extreme 6.7023
19.65
1 year 3.94
Extreme 3.94
19.65
3 years 0.92
Extreme 0.92
19.65
5 years 0.92
Extreme 0.92
19.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Exercice

General Counsel

75,000 0.1036%
8/27/26 Exercice

Director

30,000 0.0415%
8/24/26 Exercice

Chief Financial Officer

2,718 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-0.84%+1.83%+354.44%+448.48% 1.37B
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+34.08%+81.43% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-4.28%+31.24%+13.27% 25.74B
-1.11%+0.90%+23.12%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-4.68%-6.41%+560.92% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.47%+1.13%+73.41%+209.56% 28.05B
Weighted average by Cap. -0.81%+0.60%+38.52%+142.62%

Financials

2026 *2027 *
Net sales 126M 108M 102M 92.74M 173M 11.88B 174M 1.2B 466M 6.08B 472M 461M 19.38B 198M 170M 160M 146M 273M 18.71B 274M 1.9B 733M 9.58B 743M 727M 30.51B
Net income 63.3M 54.44M 51.2M 46.74M 87.41M 5.99B 87.7M 607M 235M 3.07B 238M 233M 9.77B 79.47M 68.34M 64.28M 58.68M 110M 7.52B 110M 762M 295M 3.85B 298M 292M 12.26B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-09-04 US$18.95 -0.84% 892,192
26-09-03 US$19.11 +1.33% 1,165,465
26-09-02 US$18.86 +0.59% 1,350,615
26-09-01 US$18.75 -0.21% 2,042,703
26-08-31 US$18.79 +0.97% 1,330,487
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
18.95USD
Average target price
33.00USD
Spread / Average Target
+74.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!